Gland Pharma Up 16% in 1 Month — Is This Injectable Drug Specialist the CDMO Play the Market Has Been Overlooking?

Fri Apr 10 2026

Gland Pharma has risen 16% in one month, recovering from a prolonged period of underperformance — and investors in the injectable pharmaceutical space are sitting up and taking notice. This Fosun Pharma-backed company is one of the few Indian CDMO players with genuine FDA-compliant injectable manufacturing capability at scale.

This article covers every key reason behind Gland Pharma’s recent surge, what the data says about sustainability, the short-term and long-term share price targets for 2026, and what catalysts and risks investors need to monitor before making any decision.

Click Here 2013 Get Free Investment Predictions on Univest.

About Gland Pharma (NSE: GLAND)

[Click Here – Get Free Investment Predictions on Univest.

Gland Pharma is a leading company in the Pharma / Injectable CDMO space with a market capitalisation of Rs 26,000 Cr. The stock trades at approximately 28x trailing P/E and has a 52-week range spanning from Rs 1,380 to Rs 2,100. The current price of Rs 1,580 reflects +16% appreciation 1 month, putting the stock significantly above its recent lows.

Why Is Gland Pharma Share Price Rising? The Surge Explained

Gland Pharma share price data — surge, CMP, 12M target, sector | univest.in

Tap to Access Best Research Pieces on Univest.

Gland Pharma’s Q3 FY26 revenue of Rs 1,280 crore (+14% YoY) and PAT of Rs 218 crore (+22% YoY) showed that the US injectable generic market, which had been under pricing pressure, is beginning to stabilise. The company launched 18 new products in the US in Q3 FY26, the highest in any single quarter, and its complex injectable pipeline (emulsions, suspensions, lyophilised products) is gaining regulatory approvals ahead of schedule.

Financial Performance — What the Numbers Say

The underlying financials confirm that the Gland Pharma share price surge is not just momentum — it is backed by improving fundamental performance.

Metric	Latest Quarter	Change	What It Signals
Revenue	Rs 1,280 Cr	+14% YoY	Top-line growth confirmation
Net Profit (PAT)	Rs 218 Cr	+22% YoY	Earnings acceleration
Market Cap	Rs 26,000 Cr	Current	Valuation context
Promoter Holding	58.0%	—	Management confidence
FII Holding	14.6%	—	Institutional interest

For live Gland Pharma fundamental data and peer comparison, check the Univest Screener.

Key Catalysts That Could Drive Gland Pharma Share Price Higher

• Complex injectable ANDA approvals — 40+ products in pipeline

• US FDA drug shortage list creating pricing power for legacy injectable generics

• CDMO partnerships with global pharma for outsourced injectable manufacturing

• Biosimilar injectable development for US and European markets

• Hospital injectable market growing 12-15% annually with ageing demographics

Download the Univest iOS App or Univest Android App for real-time alerts on Gland Pharma and daily SEBI-registered research.

Risks to Watch Before Chasing the Rally

• Fosun Pharma (China, 58% owner) creates regulatory and geopolitical risk in US market

• FDA warning letter risk for injectable manufacturing requires zero-tolerance quality

Not every surge is sustainable. Investors should carefully evaluate each of these risks relative to their own risk tolerance and investment horizon before making any decision. Consult a SEBI-registered financial advisor.

Technical Setup — Is the Rally Sustainable?

Gland Pharma is trading at Rs 1,580, which puts the stock +16% above its recent low of Rs 1,380 and 25% below its 52-week high of Rs 2,100. The stock has reclaimed key moving averages and technical momentum indicators (RSI, MACD) are supportive in the short to medium term. Key resistance is at the 52-week high of Rs 2,100. Short-term support is at Rs 1,550.

Subscribe to Univest Pro for live technical analysis and SEBI-registered F&O setups.

Institutional Positioning and Market Sentiment

Gland Pharma’s shareholding reflects: Promoter 58.0%, FII 14.6%, DII 12.4%. FII ownership is moderate, meaning the stock is less sensitive to global risk-off selling than FII-heavy peers. The promoter holding above 50% indicates strong founder confidence in the business.

Future Outlook — Can Gland Pharma Sustain the Rally?

Gland Pharma at 28x P/E is reasonable for a high-quality injectable CDMO with US FDA-compliant infrastructure. The 12-month target of Rs 1,900–2,200 implies 20-39% upside. Biosimilar injectable CDMO wins from global pharma would be a significant catalyst.

Gland Pharma Share Price Target 2026

Subscribe to Univest Pro for Premium Stock Research and Targets.

Short-Term Target (3-6 Months)

In the short term, Gland Pharma share price target is Rs 1,550–1,750 based on current technical positioning and the immediate momentum from the +16% 1 month surge. Support at Rs 1,550 must hold for the bullish case to remain intact.

12-Month Analyst Consensus Target

The analyst consensus 12-month Gland Pharma share price target is Rs 1,900–2,200, implying meaningful upside from the current price of Rs 1,580. This target assumes the catalysts identified in this article materialise and the macro environment remains broadly supportive.

Long-Term Target (FY27-FY28)

In a bull scenario where key catalysts deliver, the Gland Pharma share price target for FY28 is Rs 2,500–3,000. This long-term target represents a scenario where the company executes consistently and the sectoral tailwinds accelerate beyond current consensus expectations.

Track Gland Pharma live and compare with sector peers on the Univest Screener.

Conclusion

Gland Pharma’s +16% surge 1 month is backed by improving fundamentals — revenue growth of +14% YoY and PAT growth of +22% YoY in the latest quarter. The 12-month analyst consensus target of Rs 1,900–2,200 implies significant further upside from the current price of Rs 1,580. The key catalysts and risks outlined in this article are the variables that will determine whether the rally extends or corrects. Investors should evaluate both carefully before making any position decision.

This article is for informational purposes only. Please conduct your own research and consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions

Q1. Why did Gland Pharma rise 16% in 1 month?

Gland’s 16% rally was driven by Q3 FY26 PAT +22% YoY, 18 new US product launches in Q3 (a quarterly record), US injectable market stabilisation, and pipeline approval momentum.

Q2. What is Gland Pharma’s share price target 2026?

Analyst consensus 12-month target is Rs 1,900–2,200. Short-term is Rs 1,550–1,750. Long-term bull case is Rs 2,500–3,000 for FY28.

Q3. What does Gland Pharma specialise in?

Gland Pharma is a specialist injectable pharmaceutical manufacturer, producing vials, ampules, prefilled syringes, and lyophilised (freeze-dried) injectables for the US, Europe, and global markets.

Q4. Who owns Gland Pharma?

Gland Pharma is majority owned by Fosun Pharma of China (58%). The company is listed in India (NSE: GLAND). Fosun’s China connection has been a source of investor concern regarding US market access.